The therapeutic role of natural killer cells in multiple myeloma

Advances in cell and gene therapy Pub Date : 2019-01-16 DOI:10.1002/acg2.49

Ghulam Rehman Mohyuddin, Muzaffar H. Qazilbash

{"title":"The therapeutic role of natural killer cells in multiple myeloma","authors":"Ghulam Rehman Mohyuddin, Muzaffar H. Qazilbash","doi":"10.1002/acg2.49","DOIUrl":null,"url":null,"abstract":"<p>Multiple myeloma (MM) is a malignant disease of plasma cells that is also characterized by immune dysregulation. There are several factors that contribute to an immunosuppressive milieu that allows tumor progression, including alterations in natural killer (NK) cells such as a decreased expression of activating receptors. NK cells play an important role in immunosurveillance against cancer. The mainstays of myeloma therapy, such as proteasome inhibitors and immunomodulatory drugs, up-regulate the expression of activating receptors (NKG2D, DNAM-1) on NK cells thereby augmenting their activity against malignant plasma cells. Cellular therapy incorporating NK cells in both the transplant and nontransplant setting offers exciting opportunities for the future. Chimeric antigen receptor (CAR)-transduced-NK cells and bispecific antibodies utilizing NK cells have already been explored in other hematologic malignancies and hold great potential against myeloma. Future clinical studies will help in clarifying the issues related to dose, frequency, long-term safety, and efficacy of NK cell therapy in multiple myeloma.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"2 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.49","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.49","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Multiple myeloma (MM) is a malignant disease of plasma cells that is also characterized by immune dysregulation. There are several factors that contribute to an immunosuppressive milieu that allows tumor progression, including alterations in natural killer (NK) cells such as a decreased expression of activating receptors. NK cells play an important role in immunosurveillance against cancer. The mainstays of myeloma therapy, such as proteasome inhibitors and immunomodulatory drugs, up-regulate the expression of activating receptors (NKG2D, DNAM-1) on NK cells thereby augmenting their activity against malignant plasma cells. Cellular therapy incorporating NK cells in both the transplant and nontransplant setting offers exciting opportunities for the future. Chimeric antigen receptor (CAR)-transduced-NK cells and bispecific antibodies utilizing NK cells have already been explored in other hematologic malignancies and hold great potential against myeloma. Future clinical studies will help in clarifying the issues related to dose, frequency, long-term safety, and efficacy of NK cell therapy in multiple myeloma.

查看原文本刊更多论文

自然杀伤细胞在多发性骨髓瘤中的治疗作用

多发性骨髓瘤（MM）是一种浆细胞恶性疾病，其特征也是免疫失调。有几个因素导致免疫抑制环境允许肿瘤进展，包括自然杀伤（NK）细胞的改变，如激活受体的表达减少。NK细胞在癌症免疫监测中起着重要作用。骨髓瘤治疗的主要支柱，如蛋白酶体抑制剂和免疫调节药物，上调NK细胞上激活受体（NKG2D，DNAM-1）的表达，从而增强其对抗恶性浆细胞的活性。在移植和非移植环境中结合NK细胞的细胞治疗为未来提供了令人兴奋的机会。嵌合抗原受体（CAR）转导的NK细胞和利用NK细胞的双特异性抗体已经在其他血液系统恶性肿瘤中得到了探索，并具有对抗骨髓瘤的巨大潜力。未来的临床研究将有助于澄清NK细胞治疗多发性骨髓瘤的剂量、频率、长期安全性和疗效等相关问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in cell and gene therapy

自引率

0.00%

发文量